With its RNAfix platform, Shape is developing therapeutics that are designed to edit RNA in vivo by hijacking an enzyme in the target cell that naturally converts one RNA base to another.
The company raised $35.5 million in a series A this month led by NEA and boasts a scientific advisory board that includes George Church and James Collins.
The advantage of in vivo
